Report cover image

Global & United States Cancer Therapeutics Market to 2031

Publisher Business Market Insights
Published Jun 04, 2025
Length 100 Pages
SKU # BMKS20063527

Description

In 2022, the American Cancer Society reported that over 1.9 million new cancer cases were diagnosed in the United States, resulting in approximately 610,000 deaths. By 2024, the number of new diagnoses is projected to reach around 2 million. Colorectal cancer ranks as the third most commonly diagnosed cancer among both men and women in the U.S., according to the American Society of Clinical Oncology. In 2023, about 150,000 adults were diagnosed with colorectal cancer, including 106,970 cases of colon cancer (54,420 in men and 52,550 in women) and 46,050 cases of rectal cancer (27,440 in men and 18,610 in women). This growing incidence of cancer highlights the urgent need for advanced treatment options such as immunotherapies and targeted therapies. The expanding patient population is a key factor driving growth in the cancer therapeutics market as healthcare providers seek more effective approaches to treatment.

Recent FDA approvals highlight the ongoing innovation in cancer treatment. In April 2024, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) received FDA approval for the treatment of adults with unresectable or metastatic HER2-positive solid tumors who have not responded adequately to previous systemic therapies. In August 2023, the FDA approved a treatment regimen that combines the chemotherapy drugs trifluridine and tipiracil (Lonsurf) with the targeted therapy bevacizumab (Avastin) for patients with metastatic colorectal cancer who have already undergone multiple cycles of chemotherapy. Additionally, in November 2022, AstraZeneca's Imjudo (tremelimumab) was approved in combination with platinum-based chemotherapy for the treatment of Stage IV non-small cell lung cancer (NSCLC).

The growing adoption of novel therapies, especially immunotherapies and targeted treatments, is transforming cancer care. Many of these therapies are being fast-tracked by the FDA through initiatives like the Breakthrough Therapy Designation, accelerating their availability. Consequently, the combination of increasing cancer prevalence and proactive efforts by key industry players is expected to significantly boost the cancer therapeutics market in the forecast period.

Table of Contents

100 Pages
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Data Triangulation and Validation:
4. United States Cancer Therapeutics Market Landscape
4.1 Overview
4.2 Ecosystem Analysis
4.2.1 List of Vendors in the Value Chain
5. Cancer Therapeutics Market Key Market Dynamics
5.1 Cancer Therapeutics Market – Key Market Dynamics
5.2 Market Drivers
5.3 Market Restraints
5.4 Market Opportunities
5.5 Future Trends
5.6 Impact of Drivers and Restraints
6. United States Cancer Therapeutics Market – Analysis
6.1 United States Cancer Therapeutics Market Revenue (US$ Million), 2021–2031
6.2 United States Cancer Therapeutics Market Revenue and Forecast Analysis
7. United States Cancer Therapeutics Market Analysis – by Therapy Types
7.1 United States Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
8. United States Cancer Therapeutics Market Analysis – by Indications
8.1 United States Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
9. United States Cancer Therapeutics Market Analysis – by Distribution Channel
9.1 United States Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
10. Competitive Landscape
10.1 Heat Map Analysis by Key Players
10.1 Company Positioning and Concentration
11. Industry Landscape
11.1 Overview
11.2 Market Initiative
11.2 Partnerships and Collaborations
11.2 Other Developments
12. Company Profiles
12.1 Bristol-Myers Squibb Co
12.1. 1 Key Facts
12.1. 2 Business Description
12.1. 3 Products and Services
12.1. 4 Financial Overview
12.1. 5 SWOT Analysis
12.1. 6 Key Developments
12.2 AbbVie Inc
12.2. 1 Key Facts
12.2. 2 Business Description
12.2. 3 Products and Services
12.2. 4 Financial Overview
12.2. 5 SWOT Analysis
12.2. 6 Key Developments
12.3 Johnson & Johnson
12.3. 1 Key Facts
12.3. 2 Business Description
12.3. 3 Products and Services
12.3. 4 Financial Overview
12.3. 5 SWOT Analysis
12.3. 6 Key Developments
12.4 F. Hoffmann-La Roche Ltd
12.4. 1 Key Facts
12.4. 2 Business Description
12.4. 3 Products and Services
12.4. 4 Financial Overview
12.4. 5 SWOT Analysis
12.4. 6 Key Developments
12.5 Pfizer Inc
12.5. 1 Key Facts
12.5. 2 Business Description
12.5. 3 Products and Services
12.5. 4 Financial Overview
12.5. 5 SWOT Analysis
12.5. 6 Key Developments
12.6 AstraZeneca Plc
12.6. 1 Key Facts
12.6. 2 Business Description
12.6. 3 Products and Services
12.6. 4 Financial Overview
12.6. 5 SWOT Analysis
12.6. 6 Key Developments
12.7 Merck KGaA
12.7. 1 Key Facts
12.7. 2 Business Description
12.7. 3 Products and Services
12.7. 4 Financial Overview
12.7. 5 SWOT Analysis
12.7. 6 Key Developments
12.8 Novartis AG
12.8. 1 Key Facts
12.8. 2 Business Description
12.8. 3 Products and Services
12.8. 4 Financial Overview
12.8. 5 SWOT Analysis
12.8. 6 Key Developments
12.9 Astellas Pharma Inc
12.9. 1 Key Facts
12.9. 2 Business Description
12.9. 3 Products and Services
12.9. 4 Financial Overview
12.9. 5 SWOT Analysis
12.9. 6 Key Developments
12.10 Eli Lilly and Co
12.10. 1 Key Facts
12.10. 2 Business Description
12.10. 3 Products and Services
12.10. 4 Financial Overview
12.10. 5 SWOT Analysis
12.10. 6 Key Developments
13. Appendix
13.1 About Business Market Insights
13.2 List of Abbreviations
TABLE OF TABLES
Table 1. United States Cancer Therapeutics Market Segmentation
Table 2. List of Vendors
Table 3. United States Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million)
Table 4. United States Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million)
Table 5. United States Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Therapy Types
Table 6. United States Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Therapy Types
Table 7. United States Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Indications
Table 8. United States Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Indications
Table 9. United States Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 10. United States Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 11. List of Abbreviations
TABLE OF FIGURES
Figure 1. Impact Analysis of Drivers and Restraints
Figure 2. United States Cancer Therapeutics Market Revenue, (US$ Million), 2021–2031
Figure 3. Heat Map Analysis by Key Players
Figure 4. Company Positioning and Concentration

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us